Company Overview of EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc. develops, manufactures, and commercializes biosimilar products. The company offers monoclonal antibodies and therapeutic proteins. Its products include BOW015, a monoclonal antibody against tumor necrosis factor alpha. The company’s product is used to treat autoimmune diseases. It serves customers in the United States and internationally. EPIRUS Biopharmaceuticals, Inc. was formerly known as fourteen22, Inc. and changed its name to EPIRUS Biopharmaceuticals, Inc. in January 2013. The company was incorporated in 2011 and is based in Boston, Massachusetts.
699 Boylston Street
Boston, MA 02116
Founded in 2011
Key Executives for EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc. does not have any Key Executives recorded.
EPIRUS Biopharmaceuticals, Inc. Key Developments
EPIRUS Biopharmaceuticals, Inc. Announces New Board Appointments
Jul 18 14
EPIRUS Biopharmaceuticals, Inc. reported that Mark Corrigan, Julie McHugh, and William Hunter will serve on its board of directors. The board was reconstituted following the company's merger with Zalicus Inc. It also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, Kevin Buchi and Daotian Fu. Corrigan will serve as the chairman of the Epirus board. Corrigan served as a director and was the president and chief executive officer of Zalicus from 2010 to 2014. McHugh will serve on the Epirus board as a director and member of the Audit and Compensation Committees. McHugh recently served as chief operating officer for Endo Health Solutions, Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Hunter will serve on the Epirus board as a director and member of the Audit and Governance Committees. He is the president and chief executive officer of Cardiome Pharma Corp.
EPIRUS Biopharmaceuticals, Inc.(NasdaqCM:EPRS) added to NASDAQ Composite Index
Jul 16 14
EPIRUS Biopharmaceuticals, Inc will be added to the NASDAQ Composite Index.
EPIRUS Biopharmaceuticals, Inc. Announces Management Changes
Jul 15 14
On July 15, 2014, EPIRUS Biopharmaceuticals Inc., formerly known as Zalicus Inc. completed its merger with the former entity EPIRUS Biopharmaceuticals Inc. Pursuant to the terms of the Merger Agreement, effective immediately prior to the consummation of the Merger on July 15, 2014, Frank Haydu, Sally W. Crawford, Michael Kauffman and W. James O'Shea resigned from the company's board of directors. and J. Kevin Buchi, Geoffrey Duyk, Daotian Fu, Julie McHugh, Amit Munshi and Scott Rocklage were appointed as directors of the Company. Pursuant to the terms of the Merger Agreement, effective immediately after the consummation of the Merger on July 15, 2014, Mark H.N. Corrigan was terminated without cause from his position as President and Chief Executive Officer of the company, and Justin Renz was terminated without cause from his position as Executive Vice President, Chief Financial Officer, Treasurer and Secretary of the company. Amit Munshi was appointed as the company's President and Chief Executive Officer and Thomas Shea was appointed as the company's Chief Financial Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 16, 2014
April 16, 2014